NCAM1 and myotonic dystrophy type 1: Similarly, we identified significantly reduced NCAM1 expression in DM1, consistent with previous studies linking decreased NCAM1 levels in plasma to neurological impairments, including autism spectrum disorder (ASD) (Yang et al., 2019), and its role as a sensitive biomarker in sera for Charcot–Marie–Tooth disease (CMT) (Jennings et al., 2022).